Your firm must have an account to access this feature
Track this case
23-235
Supreme Court
2899 Other Statutes
The distributor of Mifeprex, the brand name of the abortion medication mifepristone, urged the U.S. Supreme Court on Tuesday to reverse the Fifth Circuit's decision upholding an "unprecedented" injunction restricting access to the pill, saying anti-abortion groups and other respondents don't have standing to challenge federal approvals of the medication.
Republican attorneys general in Missouri, Idaho and Kansas moved to join the case in the U.S. Supreme Court challenging federal approvals for the abortion medication mifepristone, asking the justices to ensure the challenge isn't dismissed for lack of standing.
A Virginia federal judge overseeing an abortion providers' suit seeking to prevent the U.S. Food and Drug Administration from revoking access to a long-approved and widely used abortion medication agreed on Friday to stay the proceedings until after the U.S. Supreme Court issues rulings in two cases that bear on the question.
When 2024 began, the U.S. Supreme Court's docket — spanning abortion, guns, social media, the modern regulatory system and more — already seemed certain to shake up the nation's cultural and economic landscapes. But now there's also a showdown involving Donald Trump and America's constitutional bedrock, auguring a truly tectonic term.
"Blockbuster," "momentous" and "historic" are all words that have been used to describe the U.S. Supreme Court's current term as the justices prepare for a spring docket jam-packed with questions over the level of deference courts should give federal agencies, whether and how social media companies should be regulated and whether government efforts to combat misinformation crosses the line between persuasion and coercion.
The 2024 appellate almanac is looking lively after eye-popping opinions and arguments in 2023's homestretch. As the new year begins, several circuit splits seem more serious, ideological imbalances are in the spotlight, and luminaries of the U.S. Supreme Court bar are locked in a burgeoning battle over alleged corporate complicity in terrorism.
The U.S. Supreme Court said Wednesday that it would review a dispute over the abortion medication mifepristone, setting up a high court battle over a lower court judge's extraordinary decision to block the U.S. Food and Drug Administration's decades-old approval of the drug.
A former BigLaw partner in his 30s made history by joining a preeminent circuit court, a former BigLaw partner in his 50s made waves by leaving the largest circuit, and a former chemist in her 90s made enemies by resisting a probe on the most specialized circuit. That's a small sample of the intrigue that flourished in 2023 throughout the federal appellate system, where diversity bloomed and controversy abounded.
The U.S. Food and Drug Administration told the U.S. Supreme Court that a Fifth Circuit decision limiting access to the abortion medication mifepristone could create "profound disruption" for patients and medical professionals, joining a distributor of the drug in urging the justices to review the "unprecedented" decision.
A strong showing for abortion rights on Election Day did not dissuade 109 GOP lawmakers from asking the U.S. Supreme Court to pass on reviewing a Fifth Circuit decision that would curb access to the abortion drug mifepristone.